Comments on: Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain

Comments on: Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain https://9krapalm.com/ractigen-therapeutics-presents-positive-phase-i-data-for-rag-17-in-sod1-als-at-the-2026-aan-annual-meeting-demonstrating-81-reduction-in-neurofilament-light-chain/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Wed, 22 Apr 2026 02:58:09 +0000 hourly 1 https://wordpress.org/?v=7.0